FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
Citi analyst Liav Abraham weighed in on Endo International plc (NASDAQ: ENDP) following news Athenex lanched a compounded Vasopressin. Abraham said the headline is likely worse than reality.
The firm reiterated a Buy rating and price target of $19.00
For an analyst... More
The downside in Endo International (NASDAQ: ENDP) (-2.7%) is related to news Athenex (NASDAQ: ATNX) announced that it had launched compounded Vasopressin injection (i.e. Vasostrict) in ready-to-use premix IV bags via Section 503B of the DQSA, RBC... More

